Do You Have Chronic Kidney Disease?

Metformin is a type of medication that is commonly used for patients with type 2 diabetes. It helps control blood sugar and can be very successful in allowing people to live a normal life while tackling their type 2 diabetes symptoms. However, people who also have chronic kidney disease, in addition to type 2 diabetes, cannot be prescribed Metformin to control their blood sugar. There is a new investigational medication that can solve this issue, and you can be one of the first people to have access to it. Keep reading to learn more about this new form of Metformin and how to sign up for the Type 2 Diabetes Clinical Trial.

Type 2 Diabetes and Chronic Kidney Disease

Insulin is a hormone made by your pancreas that acts like a key to let blood sugar into the cells in your body for use as energy. If you have type 2 diabetes, cells don’t respond normally to insulin; this is called insulin resistance. Your pancreas makes more insulin to try to get cells to respond. Eventually, your pancreas can’t keep up, and your blood sugar rises, setting the stage for prediabetes and type 2 diabetes.

Chronic Kidney Disease is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

Understanding Metformin

Metformin is an FDA-approved medication that manages high blood sugar levels in patients with type 2 diabetes. However, you should not use metformin if you have severe kidney disease, metabolic acidosis, or diabetic ketoacidosis.

If you have both Chronic Kidney Disease and type 2 diabetes, treatment can be tricky since you are not able to take the most commonly prescribed treatment method available.

Sign Up for the Type 2 Diabetes Clinical Trial

A new formulation of Metformin is being investigated in a clinical trial, and you can have exclusive access to this medication by signing up for our clinical study. The investigational formulation, called Metformin Delayed Release (DR), is designed to be absorbed in the small intestine rather than the stomach. This study will evaluate whether the DR formulation could reduce systemic exposure to metformin and lead to fewer side effects for type 2 diabetes patients with chronic kidney disease.

If you want to sign up for the study and get treatment for your type 2 diabetes with Chronic Kidney Disease, are at least 18 years of age, have type 2 diabetes, and have been taking metformin (or a medicine that contains metformin) for at least 8 weeks, have kidney function that ranges from normal to chronic kidney disease stage 3B, and do not require dialysis therapy, click here to fill out our application form.

For more information, visit us at!

By Published On: April 25, 2024Categories: ArticlesTags: , ,

Recent Posts